Navigation Links
Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009
Date:3/9/2009

SAN FRANCISCO, March 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced its fourth quarter and full year financial results for 2008 and will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. EDT (1:30 p.m. PDT) on March 10, 2009. Interested investors may participate in the conference call by dialing 877-719-9791 (US) or +1-719-325-4828 (international). Participants may also access both the live and archived webcast of the conference call, which will be available for at least 10 business days following the call, from the homepage and the investor relations section of Nile's website at www.nilethera.com.

Year-end Summary

During 2008, Nile made important progress in the clinical development of CD-NP for the treatment of patients with acute heart failure. Nile executed a focused clinical development plan for CD-NP, which included starting and completing a Phase 1b study to establish the maximum tolerated dose (MTD) and to assess the pharmacologic effects of CD-NP on blood pressure and renal function in stable heart failure patients, and also starting and completing a Phase 2a study to assess hemodynamic and renal effects of CD-NP in acute heart failure patients. Nile believes that the results of these studies indicate:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min in stable and acute heart failure patients;
  • CD-NP blood pressure effects were dose-dependent and well characterized in chronic heart failure patients;
  • In the anticipated therapeutic dose range, CD-NP produced a statistically
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics Shareholders Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
2. Cell Therapeutics Announces Receipt of NASDAQ Listing Update
3. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
4. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
5. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
6. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
7. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
8. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
9. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
10. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
11. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Erlab , ... personnel since 1968 and Burdinola, supplier of laboratory furniture ... new filtered fume hood. , By integrating ... hood, Burdinola will now offer an innovative solution utilizing ... range of chemicals, best-in-class detection technology, and communication for ...
(Date:9/23/2014)... , Sept. 23, 2014 ... the "Proteomics Markets for Research and IVD ... Technologies)" report to their offering. ... for proteomics applications, both in their research use ... proteins, including the study of the structure and ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 For the fifth ... Inc. 500|5000 list of the fastest-growing companies. , “We’re ... acknowledged yet again by Inc. Magazine,” ExakTime CEO Tony Pappas ... list by posting a three-year growth rate of 61 percent ... that time by more than 40 percent. , Pappas cited ...
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4ExakTime Makes Inc. 5000 List for the Fifth Time 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... , SILVER SPRING, Md. , Feb. ... announced today that it will release its fourth quarter and ... February 16, 2010 . , United Therapeutics will host a ... 9:00 a.m. Eastern Time .  The teleconference is accessible ...
... Ind. , Feb. 9 The American Psychiatric Association ... to prepare and manage all industry-supported symposia (ISS) programming at its ... 22-26, 2010 . , CME Enterprise will manage all elements ... partnership with the APA. , "It is a tremendous honor ...
... , , , , , , LEUVEN, ... - Paper Examines the Potential of Microplasmin to Improve the Treatment,of ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery ... today that the positive,microplasmin Phase II trial results, evaluating the product,s efficacy ...
Cached Biology Technology:CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
(Date:9/23/2014)... The successful rise and fall of an athlete,s moving body ... tendons, putting the many angles and intersecting planes literally ... joint to the test. But it,s more than just a ... devastating of sports injuries: the ACL or anterior cruciate ligament ... sits at the center of the knee joint and ...
(Date:9/23/2014)... A multidisciplinary team at the University of Wisconsin-Madison and ... more affordable way to screen for neural toxins, helping ... National Institutes of Health (NIH) announced today that the ... support to continue the promising work as part of ... will receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... award funds to support the next phase of its ... of predicting drug safety and effectiveness. Researchers will collaborate ... chips and combine them into an integrated system that ... Led by the National Center for Advancing Translational Sciences ... million in 2014 with additional support over the remaining ...
Breaking Biology News(10 mins):Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4
... just a single island in the remote South Pacific, is ... also one of the oldest flowering plants, having branched off ... Indiana University, with the U.S. Department of Energy Joint Genome ... Research for Development in New Caledonia, have determined a remarkable ...
... Ven, Department of Molecular Biology and Genetics and the ... microRNA-128 just published in Science . In the ... amount of microRNA-128 in specific neurons that react to ... in these neurons in neonatal mice, it results in ...
... a cloudless day in Dangriga, a coastal city in southern ... wall of their sun-strewn lab is lined with the usual ... tubes. Swathed in purple gloves, they measure samples, mix gels ... usual class this is not. It is part of ...
Cached Biology News:A gluttonous plant reveals how its cellular power plant devours foreign DNA 2A gluttonous plant reveals how its cellular power plant devours foreign DNA 3New research provides insight into epilepsy 2Beyond Mendel 2Beyond Mendel 3Beyond Mendel 4
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... The Dyad Disciple thermal cycler is a ... may also be operated independently, using a ... of interchangeable Alpha units (sample-holder, heat-pump assemblies), ... as the Chromo4 real-time detector. Peltier heat ...
...
I-Ab MHC Class II...
Biology Products: